Showing results (141-150 of 157) with videos related to
Sort By:
Pageof 16
European Journal of Cancer (Oxford, England : 1990)|September 27, 2021
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006Omid Hamid, Caroline Robert, Adil Daud, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With PembrolizumabF Stephen Hodi, Wen-Jen Hwu, Richard Kefford, et al.Oncogene|March 30, 2004
Microarray expression profiling in melanoma reveals a BRAF mutation signatureSandra Pavey, Peter Johansson, Leisl Packer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2016
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in MelanomaAdil I Daud, Jedd D Wolchok, Caroline Robert, et al.Nature Communications|February 28, 2013
PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanomaYan Ye, Lei Jin, James S Wilmott, et al.European Journal of Cancer (Oxford, England : 1990)|December 28, 2020
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanomaCaroline Robert, Wen-Jen Hwu, Omid Hamid, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2018
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.The New England Journal of Medicine|June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanomaKeith T Flaherty, Caroline Robert, Peter Hersey, et al.The New England Journal of Medicine|February 24, 2012
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenibJeffrey A Sosman, Kevin B Kim, Lynn Schuchter, et al.The New England Journal of Medicine|June 4, 2013
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanomaOmid Hamid, Caroline Robert, Adil Daud, et al.Pageof 16